Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice.
复制标题
DOI：
10.3390/cancers13112786
复制
发表时间：
2021-06-03
期刊：
影响因子：
5.2
通讯作者：
On Behalf Of The Kurume Liver Cancer Study Group Of Japan
中科院分区：
文献类型：
--
作者：
Iwamoto H;Shimose S;Noda Y;Shirono T;Niizeki T;Nakano M;Okamura S;Kamachi N;Suzuki H;Sakai M;Kajiwara A;Itano S;Tanaka M;Yamaguchi T;Kuromatsu R;Koga H;Torimura T;On Behalf Of The Kurume Liver Cancer Study Group Of Japan
尽管阿特珠单抗联合贝伐珠单抗的临床试验已揭示其对 HCC 的疗效，但实际临床实践的结果尚不清楚。在该研究中，我们回顾性评估了atezoizumab联合贝伐单抗治疗HCC的疗效和安全性。即使在现实世界的临床实践中，包括既往有 MTA 病史或 ALBI 1 级以外的 HCC 患者，Atezorizumab 联合贝伐单抗也是有效且安全的。背景：Atezorizumab 联合贝伐单抗被批准用于肝细胞癌 (HCC) 患者。尽管临床试验已经揭示了其功效，但现实临床实践的结果尚不清楚。我们回顾性评估了 atezolizumab 联合贝伐单抗治疗 HCC 的疗效和安全性。材料和方法：这是一项于 2020 年 11 月至 2021 年 3 月期间进行的多中心研究。在 61 名患者中，对 51 名患者的无进展生存期 (PFS)、治疗反应和不良事件 (AE) 进行了评估。结果：中位 PFS 为 5.4 个月。客观缓解率（ORR）为35.3%。疾病控制率（DCR）为86.3%。任何级别和>3级的AE发生率分别为98.0%和29.4%。任何级别和级别 >3 中最常见的 AE 是肝脏疾病。在既往有分子靶向药物（MTA）病史或白蛋白-胆红素（ALBI）分级程度的患者中，PFS、ORR、DCR 和 AE 发生率没有显着差异。结论：该研究表明，即使在现实环境中，包括既往有 MTA 病史或 ALBI 1 级以外的患者，atezolizumab 联合贝伐单抗对于 HCC 患者也是有效且安全的。
Although the clinical trial of atezolizumab plus bevacizumab have revealed its efficacy for HCC, the outcomes in the real-world clinical practice are unclear. In the study, we retorspectively evaluated the efficacy and safety of atezoizumab plus bevacizumab for HCC. Atezorizumab plus bevacizumab was effective and safe even in the real-world clinical practice including patients with HCC in a previous MTA history or other than ALBI grade 1. Background: Atezolizumab plus bevacizumab was approved for patients with hepatocellular carcinoma (HCC). Although clinical trials have revealed its efficacy, the outcomes in the real-world clinical practice are unclear. We retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC. Materials and Methods: This is a multicenter study conducted between November 2020 and March 2021. Among the 61 patients, 51 were assessed for progression-free survival (PFS), therapeutic response, and adverse events (AEs). Results: The median PFS was 5.4 months. The objective response rate (ORR) was 35.3%. The disease control rate (DCR) was 86.3%. The incidence rates of AEs at any grade and grade >3 were 98.0% and 29.4%, respectively. The most frequent AE at any grade and grade >3 was hepatic disorder. In patients with a previous history of molecular targeted agent (MTA) or the degree of albumin-bilirubin (ALBI) grade, there were no significant differences in the PFS, ORR, DCR, and incidence rates of AEs. Conclusion: The study demonstrated that atezolizumab plus bevacizumab was effective and safe for patients with HCC even in the real-world setting including patients with a previous MTA history or other than ALBI grade 1.
登录
查看更多内容
影响因子：
4.7
作者：
Malnick SDH;Abdullah A;Neuman MG
通讯作者：
Neuman MG
影响因子：
64.8
作者：
Dudek, Michael;Pfister, Dominik;Knolle, Percy A.
通讯作者：
Knolle, Percy A.
影响因子：
--
作者：
Chokr, Nora;Patel, Rima;Chokr, Samer
通讯作者：
Chokr, Samer
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
158.5
作者：
Finn, Richard S.;Qin, Shukui;Cheng, Ann-Lii
通讯作者：
Cheng, Ann-Lii